Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeuticsannounced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA.  The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection data on the company’s lead γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of older or unfit patients with newly diagnosed acute myeloid leukemia (AML).

Details of the oral presentation at ASCO 2025 are:

Abstract Title: “γ9δ2 T-cell activation with ICT01 combined with azacitidine-venetoclax for older/unfit adults with newly diagnosed AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION”

Session: Oral Abstract Session S100a - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant

Date: Monday, June 2, 2025

Time: 5:12 p.m.- 5:24 p.m. Central Time

The ASCO presentation will be available on ImCheck’s corporate website after the presentation has been held.